Figure Legends:Figure 1: (A) ROC curve of TTL of sunitinib for the prediction of grade
≥ 3 toxicity in all patients. (B) ROC curve of TTL of sunitinib for the
prediction of responders in all patients. (C) Kaplan-Meier survival
curves illustrating the progression-free survival based on TTL in all
patients.
Figure 2: (A) ROC curve of toxicity and TTL of sunitinib for the
prediction of grade ≥ 3 toxicity in patients treated with 2/1 regimen.
(B) ROC curve of TTL of sunitinib for the prediction of responders in
patients treated with 2/1 regimen. (C) Kaplan-Meier survival curves
illustrating the PFS based on TTL in patients treated with 2/1 regimen.
Supplementary Figure 2: Box and whisker plots showing trough levels of
sunitinib, SU12662 and total sunitinib at steady state (N=60). The
samples for sunitinib and SU12662 analysis was collected between days 10
to 14 in the first cycle of treatment.
Supplementary Figure 3: Waterfall plot of best response in tumour size
from baseline is shown. 8/12 (66.66%) patients who had TTL of sunitinib
< 60 ng/mL had PD whereas 4/12 (33.33%) patients had SD.
Among 18 patients who achieved TTL ≥ 82.3 ng/ml, 2 (11.11%) had PD, 13
(72.22%) patients had SD and three (16.66%) patients had PR. Out of 16
patients who had TTL of sunitinib in range of 60.75-82.3 ng/mL, one
(6.25%) patient had PD, fourteen (87.5%) patients had SD while one
patient (6.25%) had PR.